

McCormick et al
U.S. Serial No. 10/067,790
Page 6 of 7

REMARKS/ARGUMENTS

In response to the Non-Final Rejection mailed July 22, 2005, Applicants have amended, claims 51, 60 and 64, canceled claims 52, 56 and 57 without prejudice and presented the following remarks.

During the telephone interviews, the undersigned particularly urged that essentially the same principle holds for developing an anti-idiotypic vaccine by the same manner against T-cell lymphomas as such cells also have a clonal idiotypic receptor of comparable design. While the present rejection would not even apply to this embodiment, for the sake of expediting allowance of this application, the claims were amended to avoid this embodiment as well as the other traversed rejections.

Claims 51-53-54 and 56-67 were rejected under 35 USC 112, first paragraph as being enabling only for the use in a subject with a B-cell lymphoma and wherein the polypeptide includes a single chain with the Ig V_H domain and the Ig V_L domain forming the idioype.

While applicants disagree, claim 51 was so amended to avoid the rejection. Accordingly, the rejection has been overcome.

Claims 51, 53-54 and 56-67 were rejected under 35 USC 112, first paragraph as not providing a written description of the invention. The examiner urges that only the use of a polypeptide including a single chain with the Ig V_H domain and the Ig V_L domain forming the idioype for use treating a subject with a B-cell lymphoma is taught in the specification.

This is clearly wrong as even the previous set of claims shows. The specification sets forth the general nature of the invention and the applicability to other tumors with other polypeptides in several locations. Particularly note the Summary of the Invention, the definition and use of "self-antigen" and the definition and use of the term "domain".

McCormick et al
U.S. Serial No. 10/067,790
Page 7 of 7


Nonetheless, the amendment above overcomes this rejection by reciting that which the examiner indicates to be adequately supported by the written description. Accordingly, this rejection has been overcome.

In view of the above amendments and comments, the claims are now in conditions for allowance and applicants request a timely Notice of Allowance be issued in this application.

If needed, applicants petition for sufficient extension of time for consideration of this paper.

The commissioner hereby is authorized to charge payment of any fees, including extension of time fees, under 37 CFR § 1.17, which may become due in connection with the instant application or credit any overpayment to Deposit Account No.500933.

Respectfully submitted,



John E. Tarcza
Reg. No. 33,638

Date: November 22, 2005

Enclosed: Petition for a One-Month Extension of Time

John E. Tarcza
Intellectual Property Advisor
Large Scale Biology Corporation
3333 Vaca Valley Parkway, Suite 1000
Vacaville, CA 95688
301-371-7740 tel.
301-371-7745 Fax.
E-MAIL john.tarcza@lsbc.com